Call for Abstract
2nd World Conference on Breast and Cervical Cancer, will be organized around the theme “Innovations, Novel Treatment Approaches and Advance Therapies in Breast and Cervical Cancer”
BreCeCan 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in BreCeCan 2020
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Genes hold the protein-making instructions that do a lot of work in our cells. Some variations in genes can cause cells to avoid normal controls of growth and cancer. Many cancer-causing gene changes, for example, increase the development of a protein that allows cells to grow.Some result in a mistake being made, and thus non-functional, type of a protein that normally repairs cellular damage.
Cancer is a genetic disease — that is, cancer is caused by certain gene changes that regulate how our cells work, especially how they develop and divide.
There are many different types of modifications in DNA. Many changes affect just one DNA module, called a nucleotide. One nucleotide could be replaced by another, or it could be completely missing. Other modifications include wider DNA stretches, including rearrangements, deletions and duplications of long DNA stretches
Tumors reprogram nutrient acquisition and metabolism pathways to meet the demands of malignant cells that are bioenergetic, biosynthetic, and redox. These reprogrammed activities are now recognized as hallmarks of cancer, and recent work has uncovered remarkable flexibility in the specific pathways activated by tumor cells to support these key functions. From this viewpoint, we provide a theoretical framework for understanding how and why metabolic reprogramming takes place in tumor cells, and the mechanisms that link altered metabolism to tumorigenesis and metastasis. Learning these principles will slowly support the development of new human cancer treatment approaches.
Literally, the word oncology means a research division concerned with tumors and cancers. The word "onco" means tumor, mass, or bulk, while "-logy" means research. Each of the body's cells has a tightly regulated system that controls its growth, development, reproduction, and eventual death. Cancer occurs when cells start to grow out of control in a part of the body. There are many types of cancer, but they all start with the growth of abnormal cells out of control.
The field of cancer epidemiology is a diverse science and medical application area that is constantly evolving. A key focus of Cancer Epidemiology is the quantification of disease incidence and prevalence and the assessment in outcomes such as morbidity and mortality. Typically, the goal is to identify putative risk factors by comparing exposed with unexposed populations and using epidemiologic techniques including causal inference and survival analysis to assess cancer risk. . Etiologic factors may be environmental in nature (e.g., pesticides, electromagnetic fields, UV radiation, groundwater contamination, mercury in fish, indoor building-material off-gassing, cellular towers), associated with harmful behaviors (e.g., cigarette smoking, fat in diet, anal/oral sex, alcohol use, inactivity), a consequence of modern lifestyle (poor sleep, job anxiety, marital stress), attributable to innate immunologic and genetic determinants, or related to other sources (e.g., socio-economic position, discrimination).
Tumor is a rare but important cause of mortality and morbidity in neonates. Only 2 percentage of all childhood malignancies occur during the neonatal period. There is a wide spectrum of tumors, both benign and malignant, that can occur in a neonate. For a small baby even benign tumors can be life threatening because of their relative size and location, as with a large cervical teratoma and malignant potential, as with a scarococcygeal teratoma or congenital mesoblastic nephroma (CMN). Tumors that are clearly malignant may show unpredictable behavior in the neonatal period. Benign conditions like haemangioma and lymphangioma which form major differential diagnoses also have a spectrum of clinical course from benign to lethal. The British Paediatric Pathology Society estimated the prevalence of congenital neoplasia (benign and malignant) to be between 1:12,500 and 17,300 live births.2 Neonatal tumors accounted for 2 to 3 percentage of tumors diagnosed in all age groups put together and malignancies for about 1–2 percentage. Malignant tumors represented forty to fifty percentage of all diagnosed neonatal tumors.
Cancer immunology has gained renewed interest in the past few years. Undoubtedly, the resistant variant is widely recognized as a vital cancer hallmark. Basic research has revealed new goals that can be modulated with new compounds and approaches in the clinical setting. Breast cancer (BC) is verified by recent evidence.Measurement of T-infiltration lymphocytes is suggested as a powerful new tool required to predict early evolution of BC, especially in HER2-positive and triple negative subtypes. Furthermore, T-infiltration lymphocytes, genomic mechanisms and many other biomarkers in tissue and peripheral blood (e.g. regulatory T-cells and myeloid-derived suppressor cells) are not the only factors to be measured. Many on going clinical trials are exploring the activity of immune checkpoint modulators in BC treatment, both in the advanced and neo adjuvant setting. Many current clinical trials examine the role of advanced and neo-adjuvant modulators of the point of immune regulation in BC treatment. While this field progresses with exciting new discoveries and successful clinical outcomes — and raises high expectations— many obstacles remain to be overcome satisfactorily before this long-awaited therapeutic potential can be realized.
Cancer represents a huge spectrum of diseases caused by uncontrolled cell growth.. Broadly divided into benign tumors (unable to metastasize) or malignant tumors (able to invade normal tissues), cancers are The cell type, tissue or organ of origin is further identified and graded. Cancer is the number two cause of death in the United States, second only to heart disease, and the IRP is committed to advancing science, building expertise, and leveraging resources to address this global challenge. Our scientists are constantly learning more about the causes of cancer, and developing new and better ways to prevent, detect, and treat it.
The pharmacological application of nanodevices and systems is a rapidly evolving nanotechnology that creates new diagnostic and therapy possibilities for various diseases. In general in the treatment of cancer, nanotechnology has produced promising resources for chemotherapy. In the biomedical application of drugs, nanotechnology examines the structural and biochemical properties of nanoparticles. Targeted drug delivery of nanoparticles is intended to reduce the side effects of anticancer drugs with both decreased intake and treatment costs, Which are the main obstacles in the diagnosis of modern cancer. Nanoparticles ' characteristic small size and special coating allows the delivery of hydrophobic anticancer drugs to specific sites with reduced body defense mechanisms opsonization. The detection, treatment and prevention of breast cancer is one of the largest applications of nanotechnology. A large number of nanoparticles, specifically targeting metastasized breast tumors, have been created. The present study focuses on using different forms of nanoparticles in the treatment of breast cancer, including platinum, polymeric, and magnetic nanoparticles
Diagnosing cancer at its earliest stages often provides the best chance for a cure. With this in mind, talk with your doctor about what types of cancer screening may be appropriate for you. A variety of medical organizations and patient-advocacy groups have recommendations and guidelines for cancer screening. Review the various guidelines with your doctor and together you can determine what's best for you based on your own risk factors for cancer. Once cancer is diagnosed, your doctor will work to determine the extent (stage) of your cancer. Your doctor uses your cancer's stage to determine your treatment options and your chances for a cure.
A tumor is a mass of abnormal tissue. There are two types of breast cancer tumors: those that are non-cancerous, or ‘benign’, and those that are cancerous, which are ‘malignant’.
Benign Tumors: When a tumor is diagnosed as benign, doctors will usually leave it alone rather than remove it. Even though these tumors are not generally aggressive toward surrounding tissue, occasionally they may continue to grow, pressing on organs and causing pain or other problems. In these situations, the tumor is removed, allowing pain or complications to subside.
Malignant tumors: Malignant tumors are cancerous and aggressive because they invade and damage surrounding tissue. When a tumor is suspected to be malignant, the doctor will perform a biopsy to determine the severity or aggressiveness of the tumor.
There are trillions of cells in the body. These cells have a tightly regulated cell cycle that controls their growth, maturity, division and death. During childhood normal cells divide faster to allow the person to grow. Once adulthood is reached the cells divide to replace worn-out cells and to repair injuries. This cell division and growth is controlled by the cellular blue print or DNA and genes that lie within the cell’s nucleus.